Video

Dr. Esserman on Screening Patients With Higher-Risk DCIS

Laura Esserman, MD, MBA, Professor, University of California, San Francisco, discusses screening patients with higher-risk DCIS.

Laura Esserman, MD, MBA, Professor, University of California, San Francisco, discusses screening patients with higher-risk DCIS.

Chloroquine is an interesting agent, Esserman says, that may have the biologic properties to help a tumor self-destruct. A potentially-beneficial strategy may be to administer the drug for one to two weeks, then operating to determine if a patient is hitting the target or to identify a biomarker. As no drug exists that prevents ER-negative or hormone-negative disease, there is no reason not to test in this way, Esserman says.

In the case of agents like zoledronate, Esserman believes that it is a great idea to conduct a window trial to selectively screen patients with higher-risk DCIS and look for an impact.

Related Videos
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Marc-Oliver Grimm, MD
Chun Chao, PhD, MS
Mikkael A. Sekeres, MD